Pharsight

Tosymra is owned by Upsher Smith Labs.

Tosymra contains Sumatriptan.

Tosymra has a total of 8 drug patents out of which 0 drug patents have expired.

Tosymra was authorised for market use on 25 January, 2019.

Tosymra is available in spray;nasal dosage forms.

Tosymra can be used as acute treatment of migraine.

The generics of Tosymra are possible to be released after 19 July, 2031.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9283280	UPSHER SMITH LABS	Compositions for drug administration	May, 2026 (3 years from now)
US8268791	UPSHER SMITH LABS	Alkylglycoside compositions for drug administration	May, 2026 (3 years from now)
US8440631	UPSHER SMITH LABS	Compositions for drug administration	May, 2026 (3 years from now)
US11337962	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jun, 2030 (7 years from now)
US9974770	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jun, 2030 (7 years from now)
US9610280	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jun, 2030 (7 years from now)
US10603305	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jun, 2030 (7 years from now)
US9211282	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jul, 2031 (8 years from now)